ArticleJournal of translational medicine2012
Opportunities and challenges of disease biomarkers: a new section in the Journal of Translational Medicine.
Article in Journal of translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Plasma proteomics in pediatric patients with sepsis- hopes and challenges.Clinical proteomics · 2025Review
- Role of ferroptosis in colorectal cancer.World journal of gastrointestinal oncology · 2023Review
- Bioactive substances inhibiting COX-2 and cancer cells isolated from the fibrous roots ofRSC advances · 2023Article
- Article
- Dried Blood Spot (DBS) Methodology Study for Biomarker Discovery in Lysosomal Storage Disease (LSD).Metabolites · 2021Article
- An Original Ferroptosis-Related Gene Signature Effectively Predicts the Prognosis and Clinical Status for Colorectal Cancer Patients.Frontiers in oncology · 2021Article
- Identification and Validation of Ferroptosis-Related LncRNA Signatures as a Novel Prognostic Model for Colon Cancer.Frontiers in immunology · 2021Article
- Identification of Early Warning Signals at the Critical Transition Point of Colorectal Cancer Based on Dynamic Network Analysis.Frontiers in bioengineering and biotechnology · 2020Article
- Can glypican-3 be a disease-specific biomarker?Clinical and translational medicine · 2017Review
- Network biomarkers, interaction networks and dynamical network biomarkers in respiratory diseases.Clinical and translational medicine · 2014Review
- Retraction: opportunities and challenges of disease biomarkers: a new section in the Journal of Translational Medicine.Journal of translational medicine · 2013Article
Corrections and comments
- Retraction · 2013-06-06Duplication of Content through Error by Journal/Publisher ·
- Retracted
Authors and funding
2 authors.
Funding
Abstract
Disease biomarkers are defined to diagnose various phases of diseases, monitor severities of diseases and responses to therapies, or predict prognosis of patients. Disease-specific biomarkers should benefit drug discovery and development, integrate multidisciplinary sciences, be validated by molecular imaging. The opportunities and challenges in biomarker development are emphasized and considered. The Journal of Translational Medicine opens a new Section of Disease Biomarkers to bridge identification and validation of gene or protein-based biomarkers, network biomarkers, dynamic network biomarkers in human diseases, patient phenotypes, and clinical applications. Disease biomarkers are also important for determining drug effects, target specificities and binding, dynamic metabolism and pharmacological kinetics, or toxicity profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.